IRONWOOD PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Increase (Decrease) in Deferred Revenue of $225.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-02-22
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$516.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $741.00K, a 131.56% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2016-12-31 was -$4.13M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was -$4.39M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$8.99M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2015 was -$7.19M, a 1066.53% decline from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2014 was $744.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2013 was -$4.92M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$516.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $225.00K 10-Q · filed 2017-08-03 | -$3.90M derived: sum of 3 quarters · filed 2018-02-22 | -$8.29M derived: sum of 4 quarters · filed 2018-02-22 |
| 2017-03-31 | $741.00K 10-Q · filed 2017-05-08 | -$3.39M derived: sum of 2 quarters · filed 2018-02-22 | -$7.78M derived: sum of 3 quarters · filed 2018-02-22 | -$8.57M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$8.52M derived: sum of 2 quarters · filed 2018-02-22 | -$9.31M derived: sum of 3 quarters · filed 2018-02-22 | -$8.99M 10-K · filed 2018-02-22 |
| 2016-09-30 | -$4.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$5.18M derived: sum of 2 quarters · filed 2017-11-02 | -$4.86M 10-Q · filed 2017-11-02 | -$6.66M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | -$790.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$470.00K 10-Q · filed 2017-08-03 | -$2.27M derived: sum of 3 quarters · filed 2018-02-22 | -$4.07M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $320.00K 10-Q · filed 2017-05-08 | -$1.48M derived: sum of 2 quarters · filed 2018-02-22 | -$3.27M derived: sum of 3 quarters · filed 2018-02-22 | -$5.07M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$3.60M derived: sum of 2 quarters · filed 2018-02-22 | -$5.39M derived: sum of 3 quarters · filed 2018-02-22 | -$7.19M 10-K · filed 2018-02-22 |
| 2015-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$3.60M derived: sum of 2 quarters · filed 2016-11-07 | -$5.39M 10-Q · filed 2016-11-07 | -$1.90M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-06-30 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$3.60M 10-Q · filed 2016-08-08 | -$100.00K derived: sum of 3 quarters · filed 2017-02-22 | -$1.69M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-03-31 | -$1.80M 10-Q · filed 2016-05-10 | $1.70M derived: sum of 2 quarters · filed 2017-02-22 | $110.00K derived: sum of 3 quarters · filed 2017-02-22 | -$839.00K derived: sum of 4 quarters · filed 2017-02-22 |
| 2014-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $1.91M derived: sum of 2 quarters · filed 2017-02-22 | $959.00K derived: sum of 3 quarters · filed 2017-02-22 | $744.00K 10-K · filed 2017-02-22 |
| 2014-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$2.54M derived: sum of 2 quarters · filed 2015-11-05 | -$2.75M 10-Q · filed 2015-11-05 | -$4.02M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | -$949.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$1.16M 10-Q · filed 2015-08-07 | -$2.43M derived: sum of 3 quarters · filed 2016-02-19 | -$3.70M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | -$215.00K 10-Q · filed 2015-05-06 | -$1.48M derived: sum of 2 quarters · filed 2016-02-19 | -$2.75M derived: sum of 3 quarters · filed 2016-02-19 | -$4.24M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | -$1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$2.54M derived: sum of 2 quarters · filed 2016-02-19 | -$4.03M derived: sum of 3 quarters · filed 2016-02-19 | -$4.92M 10-K · filed 2016-02-19 |
| 2013-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$2.76M derived: sum of 2 quarters · filed 2014-11-05 | -$3.65M 10-Q · filed 2014-11-05 | -$4.15M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-06-30 | -$1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$2.38M 10-Q · filed 2014-08-05 | -$2.89M derived: sum of 3 quarters · filed 2015-02-18 | -$14.12M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-03-31 | -$889.00K 10-Q · filed 2014-04-29 | -$1.40M derived: sum of 2 quarters · filed 2015-02-18 | -$12.63M derived: sum of 3 quarters · filed 2015-02-18 | -$24.77M derived: sum of 4 quarters · filed 2015-02-18 |
| 2012-12-31 | -$507.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | -$11.74M derived: sum of 2 quarters · filed 2015-02-18 | -$23.88M derived: sum of 3 quarters · filed 2015-02-18 | -$36.02M 10-K · filed 2015-02-18 |
| 2012-09-30 | -$11.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$23.37M derived: sum of 2 quarters · filed 2013-10-28 | -$35.51M 10-Q · filed 2013-10-28 | -$47.65M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-06-30 | -$12.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$24.28M 10-Q · filed 2013-08-08 | -$36.42M derived: sum of 3 quarters · filed 2014-02-07 | -$48.56M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-03-31 | -$12.14M 10-Q · filed 2013-04-23 | -$24.28M derived: sum of 2 quarters · filed 2014-02-07 | -$36.42M derived: sum of 3 quarters · filed 2014-02-07 | -$47.14M derived: sum of 4 quarters · filed 2014-02-07 |
| 2011-12-31 | -$12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07 | -$24.28M derived: sum of 2 quarters · filed 2014-02-07 | -$35.00M derived: sum of 3 quarters · filed 2014-02-07 | -$45.01M 10-K · filed 2014-02-07 |
| 2011-09-30 | -$12.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$22.86M derived: sum of 2 quarters · filed 2012-11-06 | -$32.87M 10-Q · filed 2012-11-06 | -$30.34M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | -$10.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$20.73M 10-Q · filed 2012-08-07 | -$18.21M derived: sum of 3 quarters · filed 2013-02-21 | -$27.08M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | -$10.01M 10-Q · filed 2012-05-10 | -$7.49M derived: sum of 2 quarters · filed 2013-02-21 | -$16.36M derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$6.35M derived: sum of 2 quarters · filed 2013-02-21 | -$23.57M 10-K · filed 2013-02-21 | |
| 2010-09-30 | -$8.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$26.10M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$17.22M 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $53.99M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |